NCT06519357View on ClinicalTrials.gov

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions

Mild Cognitive Impairment

Interventions

DRUG

Lamivudine 300 MG

Participants receive 300 mg of Lamivudine daily for 24 weeks

Trial Locations (1)

08916

Germans Trias I Pujol Hospital, Badalona

All Listed Sponsors

collaborator

IrsiCaixa

OTHER

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT06519357 - A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) | Biotech Hunter | Biotech Hunter